Editas Medicine (EDIT) Return on Sales (2015 - 2025)

Editas Medicine (EDIT) has 11 years of Return on Sales data on file, last reported at 0.03% in Q3 2025.

• Return on Sales for Q3 2025 came in at 0.03%, up 1015.0% year-over-year; the trailing twelve-month figure through Sep 2025 was 0.04% (down 1.0% YoY), and the FY2024 annual result was 0.07%, down 5.0% from the prior year.
• Return on Sales improved to 0.03% in Q3 2025 per EDIT's latest filing, from 0.14% in the prior quarter.
• Over five years, Return on Sales peaked at 0.0% in Q4 2023 and troughed at 13.27% in Q3 2022.
• A 5-year average of 1.47% and a median of 0.09% in 2021 frame the typical range for Return on Sales.
• The sharpest annual moves came in 2022 and 2023: Return on Sales sank 1321 bps in 2022, then surged 1318 bps in 2023.
• A 5-year view of Return on Sales shows it stood at 0.03% in 2021, then plunged by 180 bps to 0.09% in 2022, then surged by 97 bps to 0.0% in 2023, then sank by 372 bps to 0.01% in 2024, then plunged by 124 bps to 0.03% in 2025.
• Business Quant data shows EDIT's Return on Sales at 0.03% in Q3 2025, 0.14% in Q2 2025, and 0.16% in Q1 2025.